Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
29 10 2020
Historique:
received: 30 06 2020
revised: 20 10 2020
accepted: 26 10 2020
entrez: 3 11 2020
pubmed: 4 11 2020
medline: 22 6 2021
Statut: epublish

Résumé

The synucleinopathy underlying multiple system atrophy (MSA) is characterized by the presence of abundant amyloid inclusions containing fibrillar α-synuclein (α-syn) aggregates in the brains of the patients and is associated with an extensive neurodegeneration. In contrast to Parkinson's disease (PD) where the pathological α-syn aggregates are almost exclusively neuronal, the α-syn inclusions in MSA are principally observed in oligodendrocytes (OLs) where they form glial cytoplasmic inclusions (GCIs). This is intriguing because differentiated OLs express low levels of α-syn, yet pathogenic amyloid α-syn seeds require significant amounts of α-syn monomers to feed their fibrillar growth and to eventually cause the buildup of cytopathological inclusions. One of the transgenic mouse models of this disease is based on the targeted overexpression of human α-syn in OLs using the PLP promoter. In these mice, the histopathological images showing a rapid emergence of S129-phosphorylated α-syn inside OLs are considered as equivalent to GCIs. Instead, we report here that they correspond to the accumulation of phosphorylated α-syn monomers/oligomers and not to the appearance of the distinctive fibrillar α-syn aggregates that are present in the brains of MSA or PD patients. In spite of a propensity to co-sediment with myelin sheath contaminants, the phosphorylated forms found in the brains of the transgenic animals are soluble (>80%). In clear contrast, the phosphorylated species present in the brains of MSA and PD patients are insoluble fibrils (>95%). Using primary cultures of OLs from PLP-αSyn mice we observed a variable association of S129-phosphorylated α-syn with the cytoplasmic compartment, the nucleus and with membrane domains suggesting that OLs functionally accommodate the phospho-α-syn deriving from experimental overexpression. Yet and while not taking place spontaneously, fibrillization can be seeded in these primary cultures by challenging the OLs with α-syn preformed fibrils (PFFs). This indicates that a targeted overexpression of α-syn does not model GCIs in mice but that it can provide a basis for seeding aggregation using PFFs. This approach could help establishing a link between α-syn aggregation and the development of a clinical phenotype in these transgenic animals.

Identifiants

pubmed: 33138150
pii: cells9112371
doi: 10.3390/cells9112371
pmc: PMC7693764
pii:
doi:

Substances chimiques

Amyloid 0
Myelin Basic Protein 0
Myelin Proteolipid Protein 0
Protein Aggregates 0
alpha-Synuclein 0
Phosphoserine 17885-08-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Neurodegener. 2017 Jul 4;12(1):52
pubmed: 28676095
J Neurol Sci. 1989 Dec;94(1-3):79-100
pubmed: 2559165
Mov Disord. 2020 Jul;35(7):1163-1172
pubmed: 32291831
J Cell Sci. 2013 Jan 15;126(Pt 2):696-704
pubmed: 23203798
Glia. 2014 Jun;62(6):964-70
pubmed: 24590631
PLoS Pathog. 2013;9(10):e1003702
pubmed: 24130496
Am J Pathol. 2005 Mar;166(3):869-76
pubmed: 15743798
Brain. 2020 Jun 1;143(6):1780-1797
pubmed: 32428221
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9593-8
pubmed: 27482103
Acta Neuropathol. 2019 Mar;137(3):455-466
pubmed: 30721406
Acta Neuropathol Commun. 2018 Jan 3;6(1):2
pubmed: 29298733
Neuron. 2005 Mar 24;45(6):847-59
pubmed: 15797547
Mov Disord. 2019 Nov;34(11):1629-1642
pubmed: 31692132
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Sci Adv. 2020 Oct 2;6(40):
pubmed: 33008896
EMBO Rep. 2002 Jun;3(6):583-8
pubmed: 12034752
Mov Disord. 2014 Mar;29(3):388-95
pubmed: 24442757
Neurobiol Dis. 2020 Jul;141:104876
pubmed: 32339655
Glia. 2014 Mar;62(3):387-98
pubmed: 24382629
Neurosci Lett. 1998 Jun 19;249(2-3):180-2
pubmed: 9682846
Mov Disord. 2019 Feb;34(2):255-263
pubmed: 30452793
Synapse. 2014 Mar;68(3):98-106
pubmed: 24243499
Am J Pathol. 2007 Oct;171(4):1291-303
pubmed: 17823288
J Neurosci. 2005 Nov 16;25(46):10689-99
pubmed: 16291942
Brain. 2017 May 1;140(5):1420-1436
pubmed: 28334990
Exp Neurol. 2010 Aug;224(2):459-64
pubmed: 20493840
Exp Neurol. 2013 Sep;247:531-6
pubmed: 23399889
Nat Neurosci. 2019 Jul;22(7):1099-1109
pubmed: 31235907
J Neurochem. 2019 Sep;150(5):612-625
pubmed: 31055836
J Neuropathol Exp Neurol. 2019 Oct 1;78(10):877-890
pubmed: 31504665
Nat Neurosci. 2019 Jan;22(1):65-77
pubmed: 30559480
Mov Disord. 2013 Mar;28(3):347-55
pubmed: 23426727
Brain. 1994 Apr;117 ( Pt 2):235-43
pubmed: 8186951
J Mol Biol. 2007 Mar 9;366(5):1510-22
pubmed: 17222866
Acta Neuropathol. 2019 Sep;138(3):415-441
pubmed: 31011860
Nature. 2020 Sep;585(7825):464-469
pubmed: 32461689
Neurosci Lett. 1998 Jul 31;251(3):205-8
pubmed: 9726379
Stem Cell Reports. 2015 Aug 11;5(2):174-84
pubmed: 26235891
Acta Neuropathol Commun. 2016 Feb 09;4:12
pubmed: 26860328
J Biol Chem. 2002 Dec 13;277(50):49071-6
pubmed: 12377775

Auteurs

Florent Laferrière (F)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.

Xin He (X)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.
Department of Neurology, Sheng Jing Hospital of China Medical University, Shenyang 110004, China.

Federica Zinghirino (F)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.
Dipartimento di Scienze Biomediche e Biotecnologiche, BIOMETEC, Università degli Studi di Catania, 95123 Catania, Italy.

Evelyne Doudnikoff (E)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.

Emilie Faggiani (E)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.

Wassilios G Meissner (WG)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.
Service de Neurologie, CRMR Atrophie Multisystématisée, CHU Bordeaux, 33000 Bordeaux, France.

Erwan Bezard (E)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.

Francesca De Giorgi (F)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.
INSERM, Laboratoire de Neurosciences Expérimentales et Cliniques, U-1084, Université de Poitiers, 86000 Poitiers, France.

François Ichas (F)

CNRS, Institut des Maladies Neurodégénératives, UMR 5293, 33076 Bordeaux, France.
Institut des Maladies Neurodégénératives, UMR 5293, Université de Bordeaux, 33076 Bordeaux, France.
INSERM, Laboratoire de Neurosciences Expérimentales et Cliniques, U-1084, Université de Poitiers, 86000 Poitiers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH